$ATNM

Actinium Pharmaceuticals, Inc.

CIK:0001388320|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenue	$ 35,000		$ 35,000
Operating expenses:
Research and development, net of reimbursements	5,377	4,879	9,578	12,579
General and administrative	2,058	2,624	3,760	11,562
Total operating expenses	7,435	7,503	13,338	24,141
Income/(Loss) from operations	27,565	(7,503)	21,662	(24,141)
Other income:
Interest income - net	336	625	717	1,325
Total other income	336	625	717	1,325
Income/(loss) before income taxes	27,901	(6,878)	22,379	(22,816)
Income tax expense
Net income/(loss)	$ 27,901	$ (6,878)	$ 22,379	$ (22,816)
Net income/(loss) per common share – basic (in Dollars per share)	$ 0.89	$ (0.22)	$ 0.71	$ (0.73)
Net income/(loss) per common share – fully diluted (in Dollars per share)	$ 0.89	$ (0.22)	$ 0.71	$ (0.73)
Weighted average common shares outstanding – basic (in Shares)	31,399,086	31,195,891	31,318,830	31,195,891
Weighted average common shares outstanding – diluted (in Shares)	31,406,740	31,195,891	31,322,144	31,195,891
Revenue
Revenue:
Total revenue
Other Revenue
Revenue:
Total revenue	$ 35,000		$ 35,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows Used in Operating Activities:
Net income/(loss)	$ 22,379	$ (22,816)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	129	9,071
Depreciation and amortization expenses	461	409
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	116	501
Accounts payable and accrued expenses	1,214	147
Operating lease liabilities	(348)	(278)
Long-term license revenue deferred	(35,000)
Net Cash Used in Operating Activities	(11,049)	(12,966)
Cash Flows Used in Investing Activities:
Purchase of property and equipment	(480)
Net Cash Used in Investing Activities	(480)
Cash Flows Used in Financing Activities:
Payments on finance leases	(5)	(5)
Net Cash Used in Financing Activities	(5)	(5)
Effect of foreign currency rates on cash	13
Net Change in Cash, Cash Equivalents and Restricted Cash	(11,521)	(12,971)
Cash, cash equivalents and restricted cash at beginning of year	48,333	73,228
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 36,812	$ 60,257

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current Assets:
Cash and cash equivalents	$ 36,473	$ 47,998
Prepaid expenses and other current assets	1,267	1,383
Total Current Assets	37,740	49,381
Property and equipment, net of accumulated depreciation of $846 and $1,064	700	295
Restricted cash – long-term	339	335
Operating leases right-of-use assets, net	1,373	1,754
Finance leases right-of-use assets, net	5	10
Total Assets	40,157	51,775
Current Liabilities:
Accounts payable and accrued expenses	8,514	7,247
Operating leases current liability	741	711
Finance leases current liability	5	11
Total Current Liabilities	9,260	7,969
Long-term license revenue - deferred		35,000
Long-term operating lease obligations	595	972
Total Liabilities	9,855	43,941
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,374,991 and 31,195,891 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	31	31
Additional paid-in capital	417,665	417,536
Accumulated other comprehensive loss	(60)	(20)
Accumulated deficit	(387,334)	(409,713)
Total Stockholders’ Equity	30,302	7,834
Total Liabilities and Stockholders’ Equity	$ 40,157	$ 51,775